Therapeutic Areas of Interest

Diabetic Peripheral Neuropathy

The World Health Organization estimates that more than 171 million people have diabetes worldwide, a figure that is expected to rise to 366 million by 2030. One major complication of diabetes is diabetic peripheral neuropathy, a painful nerve disorder that affects at least half of those who have had diabetes for 25 years or more. A market research report released in 2004 estimated the worldwide market for peripheral neuropathy (which includes diabetic neuropathy) treatments would reach $1 billion by 2012, yet to date, few treatments exist for this painful and debilitating condition.

+ More

Arthritis

An estimated 43 million Americans have been diagnosed with arthritis or similar painful joint conditions, reports the Centers for Disease Control, making it one of the nation’s most prevalent chronic health problems and a leading cause of disability.  As many as 1 in 3 adults in the United States currently suffers from chronic joint symptoms or arthritis.  Arthritis isn’t just 1 disease; it’s a complex disorder that comprises more than 100 distinct conditions and can affect people at any stage of life. Two of the most common forms are osteoarthritis and rheumatoid arthritis.

+ More

Research and Development Disclaimer

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug ("IND") or take any other action to allow its formulations to be studied or/and for any Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound, referenced herein, will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

 

 

[detail_module_foot.gif]